NNGPF

NN Group NV/ADR

OTC · CIK 0001690981
$88.57 0.00%
Vol
Exchange OTC·CIK 0001690981·Prev Close $88.57

Analyst Ratings

Historical distribution76% buy · 25 analysts · last covering-analyst action Jul 2021
4Strong Buy
15Buy
6Hold
0Sell
0Strong Sell
Historical Analyst Actions
DateFirmActionRating
Jul 21, 2021 Morgan Stanley DOWNGRADE Equal-Weight → Underweight

No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.

No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.

No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Historical analyst distribution (last covering-analyst action Jul 2021): 76% buy across 25 analysts — 4 strong buy, 15 buy, 6 hold, 0 sell, 0 strong sell. No current recommendation available.

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
$0.00 $0.00 $0.00 $0.0B
Next Q
$0.00 $0.00 $0.00 $0.0B
Current FY
2026-12-31
$0.00 $0.00 $0.00 $13.8B 4.2%
Next FY
2027-12-31
$0.00 $0.00 $0.00 $14.4B 4.0%
1 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.

Historical Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Jul 21, 2021 Morgan Stanley DOWNGRADE Equal-Weight Underweight

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 202641560076%
May 1, 202641560076%
Apr 1, 202641560076%
Mar 1, 202641560076%
Feb 1, 202641560076%
Jan 1, 202641460075%
Strong BuyBuyHoldSellStrong Sell

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.